Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.76 |
| ▸ | CA1 | P00915 | 5/20 | 0.76 |
| ▸ | CA2 | P00918 | 5/20 | 0.76 |
| ▸ | CA7 | P43166 | 5/20 | 0.76 |
| ▸ | CA9 | Q16790 | 5/20 | 0.76 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.76 |
| ▸ | CA5A | P35218 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | XDH | P47989 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46504 | 0.91 | CA12 (0.91) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4731536 | 0.91 | CA1 (0.60) | CA12CA1CA2CA7CA9 | |
| Methyl 3,5-Dihydroxybenzoate SCHEMBL38869 | 0.87 | CA1 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7307023 | 0.84 | CA5A (0.89) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14301421 | 0.83 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3351858 | 0.83 | ATM (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17274803 | 0.83 | CA12 (0.76) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1174380 | 0.83 | CA12 (0.76) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31455886 | 0.83 | CA12 (0.76) | CA12CA1CA2CA7CA9 | |
| SCHEMBL147169 | 0.82 | CA1 (0.71) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159841-A1 | MACROMOLECULAR CORROSION (MCIN) INHIBITORS: STRUCTURES, METHODS OF MAKING AND USING THE SAME | POLNOX CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | QUANTUM INTELLIGENCE CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20180201727-A1 | FUNCTIONALIZED POLYESTER POLYMERS AND FILM ARTICLES | 3M INNOVATIVE PROPERTIES COMPANY | 2018-07-19 | — | — | US | disclosed |
| US-20180079823-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20170313652-A1 | Poly-Cyanostilbene Macrocycles | NATIONAL SCIENCE FOUNDATION | 2017-11-02 | — | — | US | disclosed |
| US-9701621-B2 | Poly-cyanostilbene macrocycles | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170183419-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9611279-B2 | Zinc complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-04-04 | — | — | US | disclosed |
| US-9550787-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160222013-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2016-08-04 | — | — | US | disclosed |
| US-8980925-B2 | Antimicrobial amphiphiles and methods for their use | JAMES MADISON INNOVATIONS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150030616-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8809320-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8802667-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140148487-A1 | ANTIMICROBIAL AMPHIPHILES AND METHODS FOR THEIR USE | James Madison Innovations, Inc, (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130302357-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20120100583-A1 | Enzymatic Synthesis of Polymers | UNIVERSITY OF MASSACHUSETTS (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120100583-A1 | Enzymatic Synthesis of Polymers | UNIVERSITY OF MASSACHUSETTS (US) | 2012-04-26 | — | — | US | disclosed |
| US-20100310647-A1 | Enzymatic Synthesis of Polymers | UNIVERSITY OF MASSACHUSETTS (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CA12 2457/4885CA1 1583/4885CA2 2063/4885 |
| US-20100310647-A1 | Enzymatic Synthesis of Polymers | PNKP, MGAM, COASY | CA12 1947/4885CA1 1977/4885CA2 2330/4885 |
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | ITGB7, ITGAM, ITGA4 | CA12 2633/4885CA1 3880/4885CA2 3260/4885 |
| US-20140148487-A1 | ANTIMICROBIAL AMPHIPHILES AND METHODS FOR THEIR USE | ANXA5, ANXA4, ANXA6 | CA12 3743/4885CA1 4236/4885CA2 3241/4885 |
| US-20160222013-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CA12 2457/4885CA1 1583/4885CA2 2063/4885 |
| US-20170183419-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CA12 2457/4885CA1 1583/4885CA2 2063/4885 |
| US-20150030616-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CA12 2457/4885CA1 1583/4885CA2 2063/4885 |
| US-20170313652-A1 | Poly-Cyanostilbene Macrocycles | PCBP1, HCCS, ACVR2B | CA12 59/4885CA1 1305/4885CA2 1045/4885 |
| US-20130302357-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CA12 2457/4885CA1 1583/4885CA2 2063/4885 |
| US-20230159841-A1 | MACROMOLECULAR CORROSION (MCIN) INHIBITORS: STRUCTURES, METHODS OF MAKING AND USING THE SAME | MB, NCLN, CPN1 | CA12 34/4885CA1 15/4885CA2 201/4885 |
| US-20180079823-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CA12 2457/4885CA1 1583/4885CA2 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.